title: Protective Effect of Quercetin Against Oxidative Stress-induced Toxicity Associated With Doxorubicin and Cyclophosphamide in Rat Kidney and Liver Tissue.
abstract: BACKGROUND
  Doxorubicin and cyclophosphamide are widely used anticancer drugs with substantial toxicity in noncancerous tissue resulting from oxidative damage. Quercetin is a potent antioxidant compound. We hypothesized that quercetin administration would ameliorate the toxic effects of doxorubicin and cyclophosphamide prior to pregnancy.
  
  
  METHODS
  Cyclophosphamide, 27 mg/kg, and doxorubicin, 1.8 mg/kg, were administered to rats as intraperitoneal doses once every 3 weeks for a total of 10 weeks with or without concurrent treatment with quercetin, 10 mg/kg/d. Oxidative stress parameters were evaluated in maternal kidney and liver tissues after gestation.
  
  
  RESULTS
  Doxorubicin was associated with elevated kidney tissue malondialdehyde relative to the controls and quercetin only treatment (P < .05). Both cyclophosphamide and doxorubicin were associated with elevated malondialdehyde levels in the liver tissue (P < .05). Doxorubicin treatment was associated with decreased liver glutathione peroxidase (P < .05). Quercetin treatment suppressed the accumulation of malondialdehyde and increased glutathione peroxidase levels during doxorubicin and cyclophosphamide treatment (P <.05) Conclusions. Treatment with quercetin in patients receiving doxorubicin and cyclophosphamide results in therapeutic restoration of homeostatic expression of the antioxidant parameters, reducing oxidative damage to the liver and kidney.
authors.affiliation: Department of Physiology, Faculty of Medicine, Adiyaman University, Adiyaman, Turkey; International Scientific Center, Baku State University, Baku, Azerbaijan. sayadkocahan@gmail.com.
authors.forename: Sayad
authors.initials: S
authors.lastname: Kocahan
authors.forename: Zumrut
authors.initials: Z
authors.lastname: Dogan
authors.forename: Erman
authors.initials: E
authors.lastname: Erdemli
authors.forename: Eylem
authors.initials: E
authors.lastname: Taskin
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity; D000975:Antioxidants / Q000008:administration & dosage*; D002374:Catalase / Q000378:metabolism; D003520:Cyclophosphamide / Q000009:adverse effects*; D004317:Doxorubicin / Q000009:adverse effects*; D005260:Female; D005978:Glutathione / Q000378:metabolism; D005979:Glutathione Peroxidase / Q000378:metabolism; D007274:Injections, Intraperitoneal; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D011247:Pregnancy; D011794:Quercetin / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar; D013482:Superoxide Dismutase / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D000975:Antioxidants; D008315:Malondialdehyde; D004317:Doxorubicin; D003520:Cyclophosphamide; D011794:Quercetin; D002374:Catalase; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D005978:Glutathione